Alaunos Therapeutics, Inc., formerly known as TCR2 Therapeutics Inc., is a forward-thinking biotechnology company mainly focused on cancer immunology. Implicit in each subsidiary's name— 'Alaunos'— is the pioneering mission at its core: "to bring light into darkness," which both encapsulates its innovative drive and anticipates a brighter future for all who grapple with infirmity.
Founded in 2015, Alaunos' headquarters is in Cambridge, Massachusetts. The company operates with an underlying commitment to improve the lives of patients fighting cancer by developing cutting-edge, technologically sophisticated, 'off-the-shelf' cell therapies. Excellent science is the solid foundation upon which Alaunos has constructed its platform for curative treatments.
Alaunos' flagship technology is the TRuC-T cells—a novel class of T-cell therapies for patients suffering from solid tumors. Leveraging potent T-cell activation, these therapies possess the potential to step up as unparalleled weaponries against nefarious cancerous developments. TRuC-T cells, being "off-the-shelf", provide an opportunity for all patients, regardless of HLA type, thereby narrowing the gap for eliciting effective immune responses.
Alaunos' drug candidates are built on the scientifically established paradigm that harnessing the power of the immune system can fight cancer. The main product candidates are gavo-cel and TC-110, both being evaluated presently in phase 1/2 clinical trials, and showing promising results. They aim to target multiple antigens covering a vast array of cancers.
Just as the name suggests, Alaunos Therapeutics are pioneers, tirelessly advancing new technologies, innovations, and solutions. These promising agentries not only indicate a promising outlook for the company but also bring renewed hope for patients battling cancer. The company continually works towards exploring and developing new treatment avenues that cater to the needs of a global patient population.
Working at the intersection of high-level science and intimate patient care, Alaunos Therapeutics stands as a beacon in the overwhelmingly competitive biotech industry. Driven by the unyielding motive to elicit tangible, life-altering results and embody its name's essence, Alaunos Therapeutics, Inc., burns with an unwavering resolution. It tackles the dark, daunting landscape of cancer, aiming to provide a glimmer of hope through innovative, groundbreaking therapies.